Hemab reports HMB-002 VWD data and unveils HMB-003 program at ISTH 2026
Hemab presented HMB-002 data in Von Willebrand Disease showing dose-dependent increases in VWF and FVIII (≥2.4x at 150 mg) with a PK/PD profile suggesting monthly subcutaneous dosing. The company also unveiled HMB-003, a non-hormonal plasmin inhibitor with extended antifibrinolytic activity for heavy menstrual bleeding. ISTH 2026 could provide near-term momentum if early signals translate into durable clinical benefits.
View signal analysis